Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie-Claude Gagnieu

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
Therapie|August 9, 2011
[Evidence-based therapeutic drug monitoring for efavirenz]Caroline Solas, Marie-Claude Gagnieu,
Therapie|July 10, 2016
[Not Available]Caroline Solas, Marie-Claude Gagnieu,
Practical Laboratory Medicine|September 1, 2017
The Roche Total Mycophenolic Acid® assay: An application protocol for the ABX Pentra 400 analyzer and comparison with LC-MS in children with idiopathic nephrotic syndromeFrançois Parant, Bruno Ranchin, Marie-Claude Gagnieu
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|May 15, 2007
Relevance of a combined UV and single mass spectrometry detection for the determination of tenofovir in human plasma by HPLC in therapeutic drug monitoringMirna El Barkil, Marie-Claude Gagnieu, Jérôme Guitton
Journal of Hepatology|May 19, 2007
Ribavirin in combination therapy for HCV chronic infection in HIV patients: how to win the war after winning the first battle?Claude Souvignet, Marianne Maynard, Marie-Claude Gagnieu, et al.
Therapeutic Drug Monitoring|March 1, 2019
Dolutegravir Population Pharmacokinetics in a Real-Life Cohort of People Living With HIV Infection: A Covariate AnalysisFrançois Parant, Patrick Miailhes, Florence Brunel, et al.
Therapeutic Drug Monitoring|July 27, 2005
Hydroxyzine and metabolites as a source of interference in carbamazepine particle-enhanced turbidimetric inhibition immunoassay (PETINIA)François Parant, Mustapha Moulsma, Marie Claude Gagnieu, et al.
Current Drug Safety|January 19, 2018
Dolutegravir-Related Neurological Adverse Events: A Case Report of Successful Management with Therapeutic Drug MonitoringFrancois Parant, Patrick Miailhes, Florence Brunel, et al.
Therapeutic Drug Monitoring|November 25, 2005
No significant influence of saquinavir hard-gel capsule administration on pharmacokinetics of lopinavir in combination with ritonavir: a population approachEric Dailly, Marie-Claude Gagnieu, Clotilde Allavena, et al.
Antiviral Therapy|August 5, 2008
Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patientsMarianne Maynard, Pierre Pradat, Marie-Claude Gagnieu, et al.
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
Therapie|August 9, 2011
[Evidence-based therapeutic drug monitoring for efavirenz]Caroline Solas, Marie-Claude Gagnieu,
Therapie|July 10, 2016
[Not Available]Caroline Solas, Marie-Claude Gagnieu,
Practical Laboratory Medicine|September 1, 2017
The Roche Total Mycophenolic Acid® assay: An application protocol for the ABX Pentra 400 analyzer and comparison with LC-MS in children with idiopathic nephrotic syndromeFrançois Parant, Bruno Ranchin, Marie-Claude Gagnieu
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|May 15, 2007
Relevance of a combined UV and single mass spectrometry detection for the determination of tenofovir in human plasma by HPLC in therapeutic drug monitoringMirna El Barkil, Marie-Claude Gagnieu, Jérôme Guitton
Journal of Hepatology|May 19, 2007
Ribavirin in combination therapy for HCV chronic infection in HIV patients: how to win the war after winning the first battle?Claude Souvignet, Marianne Maynard, Marie-Claude Gagnieu, et al.
Therapeutic Drug Monitoring|March 1, 2019
Dolutegravir Population Pharmacokinetics in a Real-Life Cohort of People Living With HIV Infection: A Covariate AnalysisFrançois Parant, Patrick Miailhes, Florence Brunel, et al.
Therapeutic Drug Monitoring|July 27, 2005
Hydroxyzine and metabolites as a source of interference in carbamazepine particle-enhanced turbidimetric inhibition immunoassay (PETINIA)François Parant, Mustapha Moulsma, Marie Claude Gagnieu, et al.
Current Drug Safety|January 19, 2018
Dolutegravir-Related Neurological Adverse Events: A Case Report of Successful Management with Therapeutic Drug MonitoringFrancois Parant, Patrick Miailhes, Florence Brunel, et al.
Therapeutic Drug Monitoring|November 25, 2005
No significant influence of saquinavir hard-gel capsule administration on pharmacokinetics of lopinavir in combination with ritonavir: a population approachEric Dailly, Marie-Claude Gagnieu, Clotilde Allavena, et al.
Antiviral Therapy|August 5, 2008
Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patientsMarianne Maynard, Pierre Pradat, Marie-Claude Gagnieu, et al.
Pageof 7